Genmab and Seattle Genetics (SGI) have entered into an antibody-drug conjugate (ADC) research collaboration, under which Genmab will use SGI’s ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen in solid tumors. SGI received an undisclosed payment and has the right to exercise a co-development option for any resulting ADC products at the end of Phase I development. Genmab is responsible for research, manufacturing, and development through Phase I trials. Seattl...